Johnson & Johnson’s set to lose patent on key TB drug in July

In one of the most-watched patent cases in recent times, the Indian Patent Office on Thursday rejected American giant Johnson & Johnson’s (J&J) attempt to extend its monopoly on life-saving TB drug bedaquiline beyond July this year. The development made public coincidentally on the eve of the World TB Day — will improve access to the core drug, Bedaquiline, which is part of the WHO recommended all-oral TB regimen.

from Times of India https://ift.tt/tqpHIyg
https://ift.tt/bSZRp56
In one of the most-watched patent cases in recent times, the Indian Patent Office on Thursday rejected American giant Johnson & Johnson’s (J&J) attempt to extend its monopoly on life-saving TB drug bedaquiline beyond July this year. The development made public coincidentally on the eve of the World TB Day — will improve access to the core drug, Bedaquiline, which is part of the WHO recommended all-oral TB regimen.
In one of the most-watched patent cases in recent times, the Indian Patent Office on Thursday rejected American giant Johnson & Johnson’s (J&J) attempt to extend its monopoly on life-saving TB drug bedaquiline beyond July this year. The development made public coincidentally on the eve of the World TB Day — will improve access to the core drug, Bedaquiline, which is part of the WHO recommended all-oral TB regimen.
March 24, 2023 at 01:14AM